Kirsty

Insulin Aspart, the active ingredient in Kirsty, is a rapid‑acting insulin analog presented as a subcutaneous injection for subcutaneous use. It is used to control blood glucose in patients with diabetes mellitus, including both type 1 and type 2 disease.

GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from comprehensive regulatory support and timely delivery across global markets.

Insulin Aspart is a rapid‑acting insulin analog that lowers blood glucose by facilitating cellular uptake after meals, and it is employed in various diabetes treatment protocols. - Type 1 diabetes mellitus: provides mealtime insulin to achieve post‑prandial glucose control. - Type 2 diabetes mellitus: used as prandial insulin to reduce hyperglycemia in conjunction with oral agents. - Gestational diabetes mellitus: offers rapid glucose lowering when insulin therapy is indicated during pregnancy. - Diabetic ketoacidosis (adjunct therapy): contributes to rapid reduction of plasma glucose in intensive insulin regimens.

Insulin Aspart may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosage is excessive. - Injection site reactions: redness, swelling or itching at the injection site. - Weight gain: increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in fat tissue at injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological impairment requiring immediate assistance. - Allergic reactions: urticaria, angioedema or anaphylaxis. - Edema: peripheral swelling due to fluid retention. - Serum insulin antibodies: may alter insulin action.

When using Insulin Aspart, certain precautions should be observed to ensure safe and effective therapy. - Dose adjustment: monitor blood glucose frequently and adjust dose based on meals and activity. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose promptly. - Renal impairment: consider dose reduction as insulin clearance may be decreased. - Pregnancy and lactation: use only if benefits outweigh potential risks to mother and fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, affecting its glucose‑lowering effect or safety profile.

Major Interactions (Avoid): - Concurrent use with sulfonylureas: may markedly increase hypoglycemia risk. - Beta‑blockers: can mask hypoglycemia symptoms, complicating detection. - MAO inhibitors: may potentiate insulin’s effect leading to severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Alcohol consumption: enhances insulin action and can precipitate hypoglycemia. - Thyroid hormones: may alter insulin requirements, requiring dose reassessment. - ACE inhibitors: can affect potassium balance, necessitating monitoring.